GTMB 7 - Gene Therapy & Molecular Biology

More documents

Recommendations

Info

Gascón-Irún et al: Gene therapy antiproliferative strategies against cardiovascular diseaseKearney, M, Pieczek, A, Haley, L, Losordo, DW, Andrés, V,Schainfield, R, Rosenfield, R, and Isner, JM (1997).Histopathology of in-stent restenosis in patients withperipheral artery disease. Circulation 95, 1998-2002.Kerkhoff, E, and Rapp, UR (1997). Induction of cell proliferationin quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol CellBiol 17, 2576-2586.Kindy, MS, and Sonenshein, GE (1986). Regulation of oncogeneexpression in cultured aortic smooth muscle cells: posttranscriptionalcontrol of c-myc mRNA. J Biol Chem 261,12865-12868.Kipshidze, N, Keane, E, Stein, D, Chawla, P, Skrinska, V,Shankar, LR, Khanna, A, Komorowski, R, Haudenschild, C,Iversen, P, Leon, MB, Keelan, MH, and Moses, J (2001).Local delivery of c-myc neutrally charged antisenseoligonucleotides with transport catheter inhibits myointimalhyperplasia and positively affects vascular remodeling in therabbit balloon injury model. Catheter Cardiovasc Interv54, 247-256.Kipshidze, NN, Kim, HS, Iversen, P, Yazdi, HA, Bhargava, B,New, G, Mehran, R, Tio, F, Haudenschild, C, Dangas, G,Stone, GW, Iyer, S, Roubin, GS, Leon, MB, and Moses, JW(2002). Intramural coronary delivery of advanced antisenseoligonucleotides reduces neointimal formation in the porcinestent restenosis model. J Am Coll Cardiol 39, 1686-1691.Kotani, M, Fukuda, N, Ando, H, Hu, WY, Kunimoto, S, Saito, S,and Kanmatsuse, K (2003). Chimeric DNA-RNAhammerhead ribozyme targeting PDGF A-chain mRNAspecifically inhibits neointima formation in rat carotid arteryafter balloon injury. Cardiovasc Res 57, 265-276.Koyama, H, Olson, NE, Dastvan, FF, and Reidy, MA (1998).Cell replication in the arterial wall: activation of signalingpathway following in vivo injury. Circ Res 82, 713-721.Kume, M, Komori, K, Matsumoto, T, Onohara, T, Takeuchi, K,Yonemitsu, Y, and Sugimachi, K (2002). Administration of adecoy against the activator protein-1 binding site suppressesneointimal thickening in rabbit balloon-injured arteries.Circulation 105, 1226-1232.Kutryk, MJ, Foley, DP, van den Brand, M, Hamburger, JN, vander Giessen, WJ, deFeyter, PJ, Bruining, N, Sabate, M, andSerruys, PW (2002). Local intracoronary administration ofantisense oligonucleotide against c-myc for the prevention ofin-stent restenosis: results of the randomized investigation bythe Thoraxcenter of antisense DNA using local delivery andIVUS after coronary stenting (ITALICS) trial. J Am CollCardiol 39, 281-287.Lai, K, Lee, W-S, Jain, MK, Lee, M-E, and Haber, E (1996).Mitogen-activated protein kinase phosphatase-1 in rat arterialsmooth muscle cell proliferation. J Clin Invest 98, 1560-1567.Lambert, DL, Malik, N, Shepherd, L, Gunn, J, Francis, SE, King,A, Crossman, DC, Cumberland, DC, and Holt, CM (2001).Localization of c-Myb and induction of apoptosis byantisense oligonucleotide c-Myb after angioplasty of porcinecoronary arteries. Arterioscler Thromb Vasc Biol 21, 1727-1732.Lavia, P, and Jansen-Durr, P (1999). E2F target genes and cellcyclecheckpoint control. Bioessays 21, 221-230.Leone, G, DeGregori, J, Sears, R, Jakoi, L, and Nevins, JR(1997). Myc and Ras collaborate in inducing accumulation ofactive cyclin E/cdk2 and E2F. Nature 387, 422-426.Libby, P, and Tanaka, H (1997). The molecular basis ofrestenosis. Prog Cardiovasc Dis 40, 97-106.Lille, S, Daum, G, Clowes, MM, and Clowes, AW (1997). Theregulation of p42/p44 mitogen-activated protein kinases inthe injured rat carotid artery. J Surg Res 70, 178-186.Lloyd, AC, Obermüller, F, Staddon, S, Barth, CF, McMahon, M,and Land, H (1997). Cooperating oncogenes converge toregulate cyclin/cdk complexes. Genes Dev 11, 663-677.Lusis, AJ (2000). Atherosclerosis. Nature 407, 233-241.Maillard, L, Van Belle, E, Smith, RC, Le Roux, A, Denèfle, P,Steg, G, Barry, JJ, Branellec, D, Isner, JM, and Walsh, K(1997). Percutaneous delivery of the gax gene inhibits vesselstenosis in a rabbit model of balloon angioplasty.Cardiovasc Res 35, 536-546.Mann, M, Gibbons, GH, Kernoff, RS, Diet, FP, Tsao, PS, Cooke,JP, Kaneda, Y, and Dzau, VJ (1995). Genetic engineering ofvein grafts resistant to atherosclerosis. Proc Natl Acad SciUSA 92, 4502-4506.Mann, MJ, Gibbons, GH, Tsao, PS, von der Leyen, HE, Cooke,JP, Buitrago, R, Kernoff, R, and Dzau, VJ (1997). Cell cycleinhibition preserves endothelial function in geneticallyengineered rabbit vein grafts. J Clin Invest 99, 1295-1301.Mann, MJ, Whittemore, AD, Donaldson, MC, Belkin, M, Conte,MS, Polak, JF, Orav, EJ, Ehsan, A, Dell'Acqua, G, and Dzau,VJ (1999). Ex-vivo gene therapy of human vascular bypassgrafts with E2F decoy: the PREVENT single-centre,randomised, controlled trial. Lancet 354, 1493-1498.Mannion, JD, Ormont, ML, Magno, MG, O'Brien, JE, Shi, Y,and Zalewski, A (1998). Sustained reduction of neointimawith c-myc antisense oligonucleotides in saphenous veingrafts. Ann Thorac Surg 66, 1948-1952.Mano, T, Luo, ZY, Malendowicz, SL, Evans, T, and Walsh, K(1999). Reversal of GATA-6 downregulation promotessmooth muscle differentiation and inhibits intimalhyperplasia in balloon-injured rat carotid artery. Circ Res 84,647-654.Matsushita, H, Morishita, R, Aoki, M, Tomita, N, Taniyama, Y,Nakagami, H, Shimozato, T, Higaki, J, Kaneda, Y, andOgihara, T (2000). Transfection of antisense p53 tumorsuppressor gene oligodeoxynucleotides into rat carotid arteryresults in abnormal growth of vascular smooth muscle cells.Circulation 101, 1447-1452.Mayr, U, Mayr, M, Li, C, Wernig, F, Dietrich, H, Hu, Y, and Xu,Q (2002). Loss of p53 accelerates neointimal lesions of veinbypass grafts in mice. Circ Res 90, 197-204.McMillan, GC, and Stary, HC (1968). Preliminary experiencewith mitotic activity of cellular elements in theatherosclerotic plaques of cholesterol-fed rabbits studied bylabeling with tritiated thymidine. Ann N Y Acad Sci 149,699-709.Metzler, B, Hu, Y, Dietrich, H, and Xu, Q (2000). Increasedexpression and activation of stress-activated proteinkinases/c-Jun NH(2)-terminal protein kinases inatherosclerotic lesions coincide with p53. Am J Pathol 156,1875-1886.Miano, JM, Tota, RR, Vlasic, N, Danishefsky, KJ, andStemerman, MB (1990). Early proto-oncogene expression inrat aortic smooth muscle cells following endothelial removal.Am J Pathol 137, 761-765.Miano, JM, Vlasic, N, Tota, RR, and Stemerman, MB (1993).Localization of Fos and Jun proteins in rat aortic smoothmuscle cells after vascular injury. Am J Pathol 142, 715-724.Miniati, DN, Hoyt, EG, Feeley, BT, Poston, RS, and Robbins,RC (2000). Ex vivo antisense oligonucleotides toproliferating cell nuclear antigen and Cdc2 kinase inhibitgraft coronary artery disease. Circulation 102, III237-242.Morgan, DO (1995). Principles of CDK regulation. Nature 374,131-134.Morishita, R, Gibbons, GH, Ellison, KE, Nakajima, M, von derLeyen, H, Zhang, L, Kaneda, Y, Ogihara, T, and Dzau, VJ(1994a). Intimal hyperplasia after vascular injury is inhibited86
Gene Therapy and Molecular Biology Vol 7, page 87by antisense cdk2 kinase oligonucleotides. J Clin Invest 93,1458-1464.Morishita, R, Gibbons, GH, Ellison, KE, Nakajima, M, Zhang, L,Kaneda, Y, Ogihara, T, and Dzau, VJ (1993). Singleintraluminal delivery of antisense cdc2 kinase andproliferating-cell nuclear antigen oligonucleotides results inchronic inhibition of neointimal hyperplasia. Proc Natl AcadSci USA 90, 8474-8478.Morishita, R, Gibbons, GH, Horiuchi, M, Ellison, KE, Nakajima,M, Zhang, L, Kaneda, Y, Ogihara, T, and Dzau, VJ (1995).A gene therapy strategy using a transcription factor decoy ofthe E2F binding site inhibits smooth muscle cell proliferationin vivo. Proc Natl Acad Sci USA 92, 5855-5859.Morishita, R, Gibbons, GH, Kaneda, Y, Ogihara, T, and Dzau,VJ (1994b). Pharmacokinetics of antisenseoligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) inthe vessel wall in vivo: enhanced therapeutic utility forrestenosis by HVJ-liposome delivery. Gene 149, 13-19.Nakamura, T, Morishita, R, Asai, T, Tsuboniwa, N, Aoki, M,Sakonjo, H, Yamasaki, K, Hashiya, N, Kaneda, Y, andOgihara, T (2002). Molecular strategy using cis-element'decoy' of E2F binding site inhibits neointimal formation inporcine balloon-injured coronary artery model. Gene Ther 9,488-494.Nobuyoshi, M, Kimura, T, Ohishi, H, Horiuchi, H, Nosaka, H,Hamasaki, N, Yokoi, H, and Kim, K (1991). Restenosis afterpercutaneous transluminal coronary angioplasty: pathologicobservations in 20 patients. J Am Coll Cardiol 17, 433-439.O'Brien, ER, Alpers, CE, Stewart, DK, Ferguson, M, Tran, N,Gordon, D, Benditt, EP, Hinohara, T, Simpson, JB, andSchwartz, SM (1993). Proliferation in primary and restenoticcoronary atherectomy tissue. Implications forantiproliferative therapy. Circ Res 73, 223-231.O'Brien, ER, Urieli-Shoval, S, Garvin, MR, Stewart, DK,Hinohara, T, Simpson, JB, Benditt, EP, and Schwartz, SM(2000). Replication in restenotic atherectomy tissue.Atherosclerosis 152, 117-126.Olson, NE, Kozlowski, J, and Reidy, MA (2000). Proliferation ofintimal smooth muscle cells. Attenuation of basic fibroblastgrowth factor 2-stimulated proliferation is associated withincreased expression of cell cycle inhibitors. J Biol Chem275, 11270-11277.Orekhov, AN, Andreeva, ER, Mikhailova, IA, and Gordon, D(1998). Cell proliferation in normal and atherosclerotichuman aorta: proliferative splash in lipid-rich lesions.Atherosclerosis 139, 41-48.Parkes, JL, Cardell, RR, Hubbard, FC, Hubbard, D, Meltzer, A,and Penn, A (1991). Cultured human atherosclerotic plaquesmooth muscle cells retain transforming potential and displayenhanced expression of the myc protooncogene. Am JPathol 138, 765-775.Peeper, DS, Upton, TM, Ladha, MH, Neuman, E, Zalvide, J,Bernards, R, DeCaprio, JA, and Ewen, ME (1997). Rassignalling linked to the cell-cycle machinery by theretinoblastoma protein. Nature 386, 177-181.Perlman, H, Luo, Z, Krasinski, K, Le Roux, A, Mahfoudi, A,Smith, RC, Branellec, D, and Walsh, K (1999). Adenovirusmediateddelivery of the Gax transcription factor to ratcarotid arteries inhibits smooth muscle proliferation andinduces apoptosis. Gene Ther 6, 758-763.Perlman, H, Suzuki, E, Simonson, M, Smith, RC, and Walsh, K(1998). GATA-6 induces p21 Cip1 expression and G1 cellcycle arrest. J Biol Chem 273, 13713-13718.Philipp-Staheli, J, Payne, SR, and Kemp, CJ (2001). p27 Kip1 :regulation and function of a haploinsufficient tumorsuppressor and its misregulation in cancer. Exp Cell Res264, 148-168.Pickering, JG, Weir, L, Jekanowski, J, Kearney, MA, and Isner,JM (1993). Proliferative activity in peripheral and coronaryatherosclerotic plaque among patients undergoingpercutaneous revascularization. J Clin Invest 91, 1469-1480.Pronk, GJ, and Bos, JL (1994). The role of p21ras in receptortyrosine kinase signalling. Biochim Biophys Acta 1198,131-147.Pukac, LA, Castellot, JJ, Jr., Wright, TC, Jr., Caleb, BL, andKarnovsky, MJ (1990). Heparin inhibits c-fos and c-mycmRNA expression in vascular smooth muscle cells. CellRegul 1, 435-443.Pyles, JM, March, KL, Mehdi, K, Wilenski, RL, and Adam, LP(1997). Activation of MAP Kinase in vivo follows balloonoverstretch injury of porcine coronary and carotid arteries.Circ Res 81, 904-910.Reilly, CF, Kindy, MS, Brown, KE, Rosenberg, RD, andSonenshein, GE (1989). Heparin prevents vascular smoothmuscle cell progression through the G1 phase of the cellcycle. J Biol Chem 264, 6990-6995.Rekhter, MD, and Gordon, D (1995). Active proliferation ofdifferent cell types, including lymphocytes, in humanatherosclerotic plaques. Am J Pathol 147, 668-677.Robinson, KA, Chronos, NA, Schieffer, E, Palmer, SJ, Cipolla,GD, Milner, PG, and King, SB, 3rd (1997). Endoluminallocal delivery of PCNA/cdc2 antisense oligonucleotides byporous balloon catheter does not affect neointima formationor vessel size in the pig coronary artery model ofpostangioplasty restenosis. Cathet Cardiovasc Diagn 41,348-353.Rodriguez-Campos, A, Ruiz-Enriquez, P, Faraudo, S, andBadimon, L (2001). Mitogen-induced p53 downregulationprecedes vascular smooth muscle cell migration from healthytunica media and proliferation. Arterioscler Thromb VascBiol 21, 214-219.Roque, F, Mon, G, Belardi, J, Rodriguez, A, Grinfeld, L, Long,R, Grossman, S, Malcolm, A, Zon, G, Ormont, ML,Fischman, DL, Shi, Y, and Zalewski, A (2001a). Safety ofintracoronary administration of c-myc antisense oligomersafter percutaneous transluminal coronary angioplasty(PTCA). Antisense Nucleic Acid Drug Dev 11, 99-106.Roque, M, Reis, ED, Cordon-Cardo, C, Taubman, MB, Fallon,JT, Fuster, V, and Badimon, JJ (2001b). Effect of p27deficiency and rapamycin on intimal hyperplasia: in vivo andin vitro studies using a p27 knockout mouse model. LabInvest 81, 895-903.Rosenfeld, ME, and Ross, R (1990). Macrophage and smoothmuscle cell proliferation in atherosclerotic lesions of WHHLand comparably hypercholesterolemic fat-fed rabbits.Arteriosclerosis 10, 680-687.Ross, R (1999). Atherosclerosis: an inflammatory disease. NEngl J Med 340, 115-126.Rothman, A, Woler, B, Button, D, and Taylor, P (1994).Immediate-early gene expression in respose to hypertrophicand proliferative stimuli in pulmonary arterial smooth musclecells. J Biol Chem 269, 6399-6404.Scheinman, M, Ascher, E, Levi, GS, Hingorani, A, Shirazian, D,and Seth, P (1999). p53 gene transfer to the injured ratcarotid artery decreases neointimal formation. J Vasc Surg29, 360-369.Scott, S, O'Sullivan, M, Hafizi, S, Shapiro, LM, and Bennett, MR(2002). Human vascular smooth muscle cells from restenosisor in-stent stenosis sites demonstrate enhanced responses top53. Implications for brachytherapy and drug treatment forrestenosis. Circ Res 90, 398-404.Shi, Y, Dodge, GR, Hall, DJ, Desrochers, PE, Fard, A, Shaheen,F, Talbot, C, Yurgenev, L, and Zalewski, A (1994a).Inhibition of type 1 collagen synthesis in vascular smooth87
Page 7 and 8:
Instructions to authors:Gene Therap
Page 9:
Please submit an electronic version
Page 12:
103-111 ResearchArticle113-133 Revi
Page 17 and 18:
Gene Therapy and Molecular Biology
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50: Gene Therapy and Molecular Biology
Page 77: Gene Therapy and Molecular Biology
Page 80 and 81: Epperly et al: Late injection of Mn
Page 82 and 83: Epperly et al: Late injection of Mn
Page 84 and 85: Goldberg-Cohen et al: Regulation of
Page 90 and 91: Gascón-Irún et al: Gene therapy a
Page 106 and 107: Suzuki et al: Regulation of the Sp/
Page 114 and 115: Li et al: MET amplification in live
Page 116 and 117: Li et al: MET amplification in live
Page 118 and 119: Chavakis et al: Leukocyte adhesion
Page 128 and 129: Sanlioglu et al: Adenovirus mediate
Page 150 and 151:
George et al: Gene therapy for vasc
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Zhang et al: Angiogenic Gene Therap
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Xu et al: G-CSF receptor-mediated S
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Burek et al: Calcium induced cell d
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
David et al: Current status and fut
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Stoll et al: The role of EBV and ge
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Maruyama et al: Kidney-targeted pla
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Kren et al: Hepatocyte-targeted del
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Zeng: PRL-3 as a target for cancer
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Latchman: Protective effect of heat
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Cai et al: Lung cancer gene therapy
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309:
show all

GTMB 7 - Gene Therapy & Molecular Biology

Create successful ePaper yourself

Delete template?

Save as template?